Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Melanoma, Adenocarcinoma, Carcinoma NOS, Neuroendocrine Tumors. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Overview
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from participants' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow participants to be followed for up to 15 years following treatment on an NCI Surgery Branch Gene Therapy Trial as required by the FDA. Eligibility: Participants must have been enrolled on an NCI Surgery Branch Gene Therapy Protocol Design Participants will be followed with a physical examination and blood tests for up to 15 years as required by the FDA
Detailed description
Background:
* Patients receiving care at the NIH Clinical Center are required to be enrolled on a clinical protocol. * Following participation in a treatment protocol, it may be in the best interest of the patient to continue to be followed at the Clinical Center. * The National Cancer Institute Surgery Branch (NCI-SB) conducts clinical trials utilizing gene transfer. The current U.S. Food and Drug Administration (FDA) requirements for long-term follow-up are up to fifteen years for some products. As this time-period is frequently longer than studies are expected to be open, a long-term follow-up protocol is necessary to ensure the follow-up of these participants.
Objective:
-Primary objective:
--Provide a mechanism for long-term follow-up of participants who have participated in research studies in the NCI-SB.
Eligibility:
* Age greater than or equal to 18 years. * Participant has been enrolled on an NCI-SB treatment protocol.
Design:
* Participant will undergo physical exams, laboratory evaluation, imaging, or phone follow-up as clinically indicated. * Procedures that entail more than minimal risk to the patient should not be performed for research purposes on this protocol.
Primary outcome measures
- Long-term follow-up [Time frame: Until time of death]
Secondary outcome measures (2)
- Long-term follow-up for gene therapy studies [Time frame: 15 years]
- Survival [Time frame: Until time of death]
Eligibility criteria
- INCLUSION CRITERIA:
- Age greater than or equal to 18 years.
- Participants who have received treatment on an NCI-SB protocol, including gene therapy protocols. (Note: Participants may be enrolled on this protocol and, at the same time, participate in an active treatment study).
- For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. For Cohort B: Participant is able to provide informed consent.
Exclusion criteria
-For Cohort B: Individuals of child-bearing potential (IOCBP) who are pregnant or plan to become pregnant because of the potentially dangerous effects of the investigational treatments administered on NCI-SB treatment protocols.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- National Institutes of Health Clinical Center — Bethesda
Identifiers
NCT: NCT00923026 · 090161 · 09-C-0161